Abstract

IDEX Corporation will release its first-quarter 2026 financial results on April 29, 2026 Pre-Market, and consensus points to year-over-year growth in revenue and adjusted EPS as we review the last quarter’s mix, margins, and the setup for Health & Science Technologies and other core businesses.

Market Forecast

Consensus for the first quarter of 2026 anticipates revenue of 845.44 million US dollars, up 4.74% year over year, adjusted EPS of 1.77, up 8.55% year over year, and EBIT of 160.63 million US dollars, up 6.67% year over year; margin forecasts have not been widely published, so investors will benchmark outcomes against last quarter’s 43.05% gross margin and 14.27% net profit margin. Within the portfolio, the latest reported period showed a balanced mix that supported mid-40s gross margins, and the market expects modest year-over-year expansion in earnings per share despite a sequential revenue step-down from the prior quarter’s seasonal high. Health & Science Technologies, the largest revenue contributor at 407.70 million US dollars in the last reported quarter, remains the central driver to near-term performance on both volume and mix. Among segments, Health & Science Technologies presents the strongest near-term potential given its scale and contribution to consolidated growth, with the company’s last quarter revenue rising 4.20% year over year and this segment anchoring the bulk of absolute revenue.

Last Quarter Review

In the prior quarter, IDEX Corporation delivered revenue of 899.10 million US dollars, a 4.20% year-over-year increase, with a 43.05% gross profit margin, 128.00 million US dollars in net profit attributable to the parent, a 14.27% net profit margin, and adjusted EPS of 2.10, up 2.94% year over year. A key highlight was profitability: EBIT of 220.20 million US dollars exceeded consensus by 18.41%, while net profit rose 39% sequentially, underscoring robust operating execution into year-end. Main business composition underscored stability in the core: Health & Science Technologies generated 407.70 million US dollars, Fluid & Metering Technologies 305.50 million US dollars, and Fire & Safety/Diversified Products 187.60 million US dollars, with intersegment eliminations of 1.70 million US dollars, anchoring the company’s 4.20% year-over-year revenue growth.

Current Quarter Outlook

Main business trajectory and delivery cadence

The first quarter setup features a consensus revenue expectation of 845.44 million US dollars, indicating a typical sequential step-down from the prior quarter’s 899.10 million US dollars but a 4.74% increase from the year-ago period. That year-over-year growth is paired with an 8.55% increase in adjusted EPS to 1.77 and EBIT growth of 6.67% to 160.63 million US dollars, framing an earnings cadence supported by operating discipline and mix. With last quarter’s gross margin at 43.05% and net profit margin at 14.27%, investors will watch how price-cost discipline, product mix, and volume leverage translate to margins this quarter, particularly as revenue normalizes from the fourth-quarter seasonal high. Within the core portfolio, Health & Science Technologies and Fluid & Metering Technologies together accounted for roughly 79% of last quarter’s reported revenue, highlighting the areas most likely to set the tone for consolidated performance. As volume shifts into the first quarter, mix between these businesses will be central to gross margin direction, since even small changes in the proportion of higher- versus lower-margin product and project revenue can move consolidated margins. Management’s expense discipline exiting the prior quarter, together with measured cost control and productivity, should help preserve drop-through to EBIT in a mid-single-digit year-over-year revenue growth environment, consistent with the consensus calling for EBIT of 160.63 million US dollars. Operating metrics will be judged not only on reported revenue but also on the quality of earnings—namely gross margin progression from 43.05%, stability in operating expenses as a percent of sales, and the relationship between revenue, earnings, and cash generation. With adjusted EPS expected at 1.77, the comparison to last quarter’s 2.10 emphasizes that margins and conversion will be scrutinized for signs that structural cost initiatives and mix management are holding up even as volumes recalibrate from fourth-quarter levels.

Most promising business: Health & Science Technologies

Health & Science Technologies delivered 407.70 million US dollars in the last reported quarter and remains the largest contributor to group revenue. Its scale positions it as a primary lever for consolidated earnings, as variations in demand and shipment timing can have an outsized effect on both revenue and margins due to its weight in the portfolio. The segment’s contribution, together with company-wide year-over-year revenue growth of 4.20% in the last quarter, supports the market’s view that near-term gains are achievable even in a sequentially lower volume quarter. The near-term focus for this business centers on delivery cadence and product mix—two elements that can influence gross margin around the prior quarter’s 43.05% level. As order fulfillment evolves through the quarter, investors will be attentive to whether higher-value, engineered products maintain a healthy mix versus more standardized offerings, which would help protect margins and support the consensus step-up in adjusted EPS year over year. Because Health & Science Technologies represents the largest single revenue pool reported by the company, modest improvements in throughput and mix can drive disproportionate earnings impact relative to peers within the portfolio. From a stock setup standpoint, commentary around demand stability, backlog quality, and the phasing of shipments within the quarter will be important for gauging whether the first-quarter profile can keep adjusted EPS on track relative to the 1.77 consensus. Any evidence that price discipline or cost efficiencies continue to offset input and logistics variability would also reinforce confidence in margin resilience despite the sequential revenue step-down from 899.10 million US dollars to 845.44 million US dollars expected by the market.

Key stock-price swing factors this quarter

The first determinant is margin trajectory versus the prior quarter: investors will compare reported gross margin to 43.05% and net profit margin to 14.27% to assess how mix and cost control are shaping profitability. A result that keeps gross margin broadly stable, even on lower sequential revenue, would validate the operating model and support the 8.55% year-over-year growth implied for adjusted EPS. Conversely, any unexpected contraction from the 43.05% baseline would raise questions about mix and cost absorption and could translate into earnings variance against the 1.77 EPS expectation. A second swing factor is management’s qualitative commentary relative to full-year guardrails. The company’s previously communicated full-year 2026 adjusted EPS framework of 8.15–8.35 offers context for quarterly execution, and alignment of first-quarter trends with that range would be interpreted positively by the market. Updates on order flow and shipment timing across core businesses—particularly the largest reported driver, Health & Science Technologies at 407.70 million US dollars in the last quarter—will inform whether mid-single-digit year-over-year growth assumptions remain appropriate for the near term. A third factor is the balance between revenue and EBIT, given consensus calls for 160.63 million US dollars of EBIT this quarter after a stronger 220.20 million US dollars in the prior period. Investors will evaluate operating leverage by comparing the change in revenue to the change in EBIT and will likely focus on whether disciplined expense management and productivity can sustain earnings growth year over year. Clear signals that costs are tracking with volumes and that pricing actions remain in place would support the projected 6.67% EBIT growth and help underpin confidence in the 1.77 adjusted EPS target.

Analyst Opinions

Based on collected views, the majority stance is bullish (bullish 1, bearish 0), reflecting a constructive setup anchored by consensus expectations. FactSet’s aggregated view points to first-quarter 2026 revenue of 845.44 million US dollars and adjusted EPS of 1.77, implying year-over-year growth of 4.74% and 8.55%, respectively, while the company’s full-year 2026 adjusted EPS framework of 8.15–8.35 brackets the prevailing 8.30 full-year consensus. The combination of positive year-over-year earnings growth in the quarter and alignment between management’s full-year framework and consensus supports a favorable near-term bias in institutional expectations. The bullish angle emphasizes consistency in execution and margin stewardship into the new fiscal year. Last quarter’s results provide evidence for this view: EBIT of 220.20 million US dollars exceeded expectations by 18.41%, and net profit rose 39% sequentially, offering a strong baseline against which to judge first-quarter margin dynamics. With consensus already embedding a sequential step-down in revenue, upside would most likely come from better-than-expected gross margin versus the 43.05% benchmark or tighter operating expenses that allow EBIT to track closer to prior-quarter levels than currently modeled. Bullish previews also highlight the segment mix as manageable for earnings quality. Health & Science Technologies, with 407.70 million US dollars in last quarter revenue, remains the largest contributor to profit drivers, and incremental improvements in delivery cadence and mix can influence consolidated margins at the group level. If first-quarter results show that price, cost, and mix measures are holding—evidenced by gross margin tracking close to last quarter’s 43.05% despite lower sequential volume—then the implied 8.55% adjusted EPS growth could prove conservative, reinforcing the positive tone in institutional expectations. From a valuation and expectations standpoint, the constructive view recognizes that the market is not calling for outsized revenue acceleration in the first quarter, but rather steady mid-single-digit growth with prudent cost control. This keeps the burden of proof on margin and conversion, areas where the company demonstrated strength at year-end. Should the report affirm that gross margin remains near the high-30s to low-40s range consistent with the last quarter’s 43.05% and that EBIT tracks close to the 160.63 million US dollars consensus, the path to meeting or modestly exceeding the 1.77 EPS target appears achievable, which aligns with the bullish skew in institutional commentary.